BiosimilarsCME.org offers educational opportunities and resources to help clinicians improve their knowledge and competence in the use of biosimilars across multiple therapeutic areas.
http://www.biosimilarscme.org/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
3.2 seconds
The France Foundation
The France Foundation
230 ●●●●e rd
Old●●●yme , CT, 06371
US
View this contact
The France Foundation
The France Foundation
230 ●●●●e rd
Old●●●yme , CT, 06371
US
View this contact
The France Foundation
The France Foundation
230 ●●●●e rd
Old●●●yme , CT, 06371
US
View this contact
BUY YOUR DOMAIN
Network Solutions, LLC (R63-LROR)
WHOIS : whois.publicinterestregistry.net
REFERRED :
PAGES IN
THIS WEBSITE
10
SSL
EXTERNAL LINKS
8
SITE IP
38.106.217.139
LOAD TIME
3.225 sec
SCORE
6.2
BiosimilarsCME.org - Welcome | biosimilarscme.org Reviews
https://biosimilarscme.org
BiosimilarsCME.org offers educational opportunities and resources to help clinicians improve their knowledge and competence in the use of biosimilars across multiple therapeutic areas.
biosimilarscme.org
Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic and Pharmacodynamic Equivalence to Amgen's Epogen
http://www.biosimilarscme.org/newsfeed/39-clinical-data-shows-proposed-biosimilar-epoetin-hospira-demonstrates-pharmacokinetic-and-pharmacodynamic-equivalence-to-amgen-s-epogen
Abstract News 2015 INFORMATION, INC. Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics. Biosimilars on the Horizon in the US: A Review of What’s Coming and the European Experience.
Live Meeting Request
http://www.biosimilarscme.org/live-meeting-request
Interested in hosting a Biosimilars activity? The Biosimilars faculty will bring knowledge and understanding of the potential role Biosimilars are expected to play in treatment regiments in hematology to your Grand Rounds series, State Chapter Meeting, or other local event. Request a live meeting in your area now! Would you like The France Foundation to provide CME accreditation? No, we will provide the accreditation. Please list three available dates. Please list three potential speakers.
CMS Biosimilar Part B and Part D Guidance
http://www.biosimilarscme.org/newsfeed/37-cms-biosimilar-part-b-and-part-d-guidance
Centers for Medicare and Medicaid Services (03/30/15). Abstract News 2015 INFORMATION, INC. Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics. Biosimilars on the Horizon in the US: A Review of What’s Coming and the European Experience.
Amgen Loses Bid to Block a Biosimilar Version of Its Best-Selling Drug
http://www.biosimilarscme.org/newsfeed/38-amgen-loses-bid-to-block-a-biosimilar-version-of-its-best-selling-drug
Wall Street Journal (03/20/15) Silverman, Ed. Abstract News 2015 INFORMATION, INC. Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics. Biosimilars on the Horizon in the US: A Review of What’s Coming and the European Experience.
BiosimilarsCME.org - About Biosimilars
http://www.biosimilarscme.org/about-biosimilars
FDA http:/ www.fda.gov/. Weiss M, Bielsky MC, De Smet K, et al. Lucio S, Stevenson, J, Hoffman J. Am J Health Syst Pharm. 11-Minute Tutorial on Biosimilars. Listen to Dr. Edward Li describe the similarities and differences between biosimilars and reference biologics, and review current FDA regulation guidance. Click here to access our full range of educational activities. Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics.
TOTAL PAGES IN THIS WEBSITE
10
Education
http://www.francefoundation.com/education
Ensuring Postoperative Safety and Comfort from Neuromuscular Blockade. Intraoperative use of muscle relaxants and postoperative residual neuromuscular block have been identified as key risk factors in anesthetic-related morbidity and mortality. Residual neuromuscular block in the postoperative phase is increasingly recognized as a complication of the use of nondepolarizing muscle relaxants (NDMRs). The ABCs of Accredited CME. PILOT is a national education initiative designed to provide physicians with a.
BiosimilarsCME.org: One Click to the Portal for Biosimilars Educational Needs
http://www.francefoundation.com/biosimilarscme-org-one-click-to-the-portal-for-biosimilars-educational-needs
BiosimilarsCME.org: One Click to the Portal for Biosimilars Educational Needs. OLD LYME, CT — JUNE 2, 2015 —The first biosimilar was approved in the US in March, and there are many more approvals anticipated. The introduction of biosimilars into the US market is expected to expand patient access to biologic therapies and reduce health care costs. To access the website, please visit www.biosimilarscme.org. Is the Patient Voice Being Heard in Medical Education? PILOT Connect: The Latest in IPF.
BiosimilarsCME.org: One Click to the Portal for Biosimilars Educational Needs
http://dev.francefoundation.com/biosimilarscme-org-one-click-to-the-portal-for-biosimilars-educational-needs
One Click to the Portal for Biosimilars Educational Needs. The first biosimilar was approved in the US in March, and there are many more approvals anticipated. The introduction of biosimilars into the US market is expected to expand patient access to biologic therapies and reduce health care costs. To access the website, please visit www.biosimilarscme.org. On the Cutting Edge of Personalized Medicine: Genetics and Genomics. Is the Patient Voice Being Heard in Medical Education?
Education
http://dev.francefoundation.com/education
Ensuring Postoperative Safety and Comfort from Neuromuscular Blockade. Intraoperative use of muscle relaxants and postoperative residual neuromuscular block have been identified as key risk factors in anesthetic-related morbidity and mortality. Residual neuromuscular block in the postoperative phase is increasingly recognized as a complication of the use of nondepolarizing muscle relaxants (NDMRs). Extended-Release and Long-Acting Opioids: Assessing Risks, Safe Prescribing. The ABCs of Accredited CME.
TOTAL LINKS TO THIS WEBSITE
8
STRATO
Home | Biosimilars Asia Pacific 2015 Conference - IBC Asia
Skip to main content. 27 Oct 2015 - 30 Oct 2015. Grand Copthorne Waterfront Hotel, Singapore. Focused Biosimilars event in Singapore. Latest Biosimilar Case Studies. Over the past year, the number of biosimilar development projects which have been publically disclosed has increased by approximately 40 percent with demand in Asia gaining momentum. Evaluates the region’s market readiness and future uptake of biosimilars, development of regulatory frameworks and best practice commercialization strategies.
Oxford Global Conferences – Biopharma Asia Congress 15-16 October 2015 in Singapore
Oxford Global Conferences – Biopharma Asia Congress 15-16 October 2015 in Singapore. Biopharma Asia Series 2015. Biopharma Asia Series 2015. Agenda at a glance. Biopharma Asia Series 2015. Is proud to present the Biopharma Asia Series. Taking place on 15-16 October 2015. The series is dedicated to discussing scientific trends and addressing the most pressing challenges in the Asia Biopharmaceutical industry, made up of two co-located events Biosimilars Asia Congress. And the Cell Culture Asia Congress.
Biosimilars Asia Congress, 22-23 September 2015, Singapore
Biosimilars Asia Congress, 22-23 September 2015, Singapore. Biosimilars Asia Congress 2015. Biosimilars Asia Congress 2015. Over 175 attendees working within Biosimilars. Over 20 case studies, presentations and panel discussions. Biosimilars: Market Opportunities, Manufacture and Scale-Up. Developing Biosimilars: Opportunities and Challenges In Clinical Trials. 14 pre-scheduled one to one meetings, exhibition and informal networking opportunities. Are proud to present the Biosimilars Asia Congress. Our p...
Home | 6th Annual Biosimilars Asia 2015 Conference - IBC Asia
Skip to main content. 19 May 2015 - 22 May 2015. Grand Hyatt Shanghai, China. 6th Annual Biosimilars Asia 2015. Asia’s leading and most highly-anticipated event. Highlights on market access and commercialization case study. The region’s largest gathering of leading and future stakeholders across the value chain. Biosimilars Asia Conference,. Why you should attend. Gain in-depth content from leading biosimilars companies and case studies on market access and commercialization strategies. Learn innovative ...
BiosimilarsCME.org - Welcome
Offers educational opportunities and resources to help clinicians improve their knowledge and competence in the use of biosimilars across multiple therapeutic areas. Infliximab-qbtx Approved by FDA. First Trastuzumab Biosimilar, Ogivri, Approved by FDA. Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics.
biosimilarsCMO - Home
Join our mailing list now for our first report:. The Top Biological CMO Companies in the World. Fill out the form below to receive this free report. thanks! What to look for in a cGMP biological CMO. Years preferably decades. of experience. Personal service; focus on CMOs who are smaller and treat your project as. Their most important one. Strong global regulatory experience. A clean FDA Establishment Inspection Report. A willingness to share several references to speak with. Flexibility in doing business.
Biosimilars Conference
The Belgian Biosimilars Conference. From clinical experience to practical implementation. 15 April 2016 Promotiezaal, KU Leuven. In light of the recently concluded Convenant voor de doorstart voor biosimilaire geneesmiddelen in België/Convention sur la relance des médicaments biosimilaires en Belgique , the conference focuses on how physicians and hospital management can practically start implementing biosimilars in Belgian hospitals. Conference chair: Prof. Dr. René Westhovens. Prof Dr. Geert D’Haens.
The Biosimilars Council | A Division of GPhA
About the Biosimilars Council. The GPhA Biosimilars Council works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars. Areas of focus will include education, access, the nascent regulatory environment, reimbursement and legal affairs. Member organizations include any company or stakeholder organization working to develop biosimilar products with the inte...
biosimilarsdatabase.com - This website is for sale! - biosimilars Resources and Information.
The owner of biosimilarsdatabase.com. Is offering it for sale for an asking price of 1350 USD! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
Biosimilars Europe Congress 2017 | Global Event in Biosimilars and Biobetters | International Conference at London, U.K on 21 Nov 2017
Download 2017 Sales Brochure. Become a Sponsor / Exhibit. 2016 Sponsor and Exhibitors. Navigating through the new waves of Biologics. Developing Biosimilars Market in Europe. Your browser does not support the video tag. I suggest you upgrade your browser. Head Global Medical Affairs Biosimilars. Marketing Director - Provantage E2E Services Process Solutions. Senior Regulatory Affairs Manager. Dr Mourad Farouk Rezk MD. Global Head Medical Affairs Biosimilars. Lead Risk Management, Global Pharmacovigilance.
